abiraterone
Sign in to saveAlso known as CB 7598, (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-pyridyl)androsta-5,16-dien-3beta-ol
REDIRECT Abiraterone acetate
Research
4,108 papers- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.Lancet (London, England) · 2022
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.The Lancet. Oncology · 2023
- Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.NEJM evidence · 2022
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
- AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.The New England journal of medicine · 2014
via PubMed
~1 min read
Encyclopedic overview
REDIRECT Abiraterone acetate
Excerpted from Wikipedia’s “abiraterone” article, available under the CC BY-SA 4.0 licence.